Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Dasatinib in Relapsed/Refractory Ph+ ALL
NCT02819804Phase 1Terminated
- Sponsor
- Northwestern University
- Start
- Aug 2017
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in acute lymphoblastic leukemia (ALL), sponsored by Northwestern University. Primary endpoint: Incidence of Dose-Limiting Toxicity at 28 days. Started Aug 2017; status: terminated.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02819804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02819804.